tiprankstipranks
Aspen Pharmacare (APNHY)
OTHER OTC:APNHY
Holding APNHY?
Track your performance easily

Aspen Pharmacare (APNHY) Income Statement

18 Followers

Aspen Pharmacare Income Statement

Last quarter (Q2 2023), Aspen Pharmacare's total revenue was Rs19.15B, an increase of 2.77% from the same quarter last year. In Q2, Aspen Pharmacare's net income was Rs―. See Aspen Pharmacare’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 23Jun 22Jun 21Jun 20Jun 19
Total Revenue
Rs 95.52BRs 40.71BRs 38.61BRs 37.77BRs 33.66BRs 35.51B
Cost of Revenue
--Rs 20.30BRs 19.98BRs 16.52BRs 16.97B
Gross Profit
--Rs 18.31BRs 17.79BRs 17.14BRs 18.54B
Operating Expense
--Rs 9.47BRs 9.66BRs 9.03BRs 9.65B
Operating Income
--Rs 8.84BRs 8.13BRs 8.11BRs 8.89B
Net Non Operating Interest Income Expense
--Rs -673.00MRs -1.14BRs -1.51BRs -2.08B
Other Income Expense
------
Pretax Income
--Rs 8.13BRs 5.99BRs 4.20BRs 2.35B
Tax Provision
--Rs 1.65BRs 1.19BRs 818.00MRs 671.00M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
--Rs 6.49BRs 4.81BRs 4.66BRs 6.46B
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
--Rs 50.00MRs 84.00MRs 21.00MRs 123.00M
Total Expenses
--Rs 29.77BRs 29.64BRs 25.55BRs 26.62B
Net Income From Continuing And Discontinued Operation
--Rs 6.49BRs 4.81BRs 4.66BRs 6.46B
Normalized Income
--Rs 6.56BRs 5.56BRs 4.91BRs 5.02B
Interest Expense
--Rs 765.00MRs 1.21BRs 1.65BRs 2.23B
EBIT
--Rs 8.90BRs 7.19BRs 5.85BRs 4.58B
EBITDA
-Rs 9.67BRs 10.61BRs 8.85BRs 7.45BRs 5.85B
Currency in ZAR

Aspen Pharmacare Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis